source
- Sanofi says no major restructuring despite upcoming Dupixent patent expirationSanofi's new chief executive, Belén Garijo, said after six months in charge that the company will not embark on a major overhaul of its business or research pipeline. The comment was made as the b…
- AstraZeneca launches $1.5 billion annual cost-saving plan to offset late-stage trial setbacksAstraZeneca announced a new cost‑saving initiative targeting $1.5 billion of annual expenses. The move follows a series of late‑stage clinical trial failures that have pressured the company's pipe…